A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma

Gynecologic Oncology

Volumn 130, Issue 1, 2013, Pages 25-30

  Herzog, Thomas J ^a   Scambia, Giovanni ^b   Kim, Byoung Gie ^c   Lhommé, Catherine ^d   Markowska, Janina ^e   Ray Coquard, Isabelle ^f   Sehouli, Jalid ^g   Colombo, Nicoletta ^h,i   Shan, Minghua ^j   Petrenciuc, Oana ^k   Oza, Amit ^l  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f CENTRE LÉON BÉRARD   (France)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY OF MILANO BICOCCA   (Italy)

ⁱ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^j BAYER CORPORATION   (United States)

^k University of Toronto ^*

^l UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Epithelial ovarian cancer; Maintenance therapy; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN; PLACEBO; SORAFENIB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; HYPERTENSION; LIMB PAIN; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; OVARY CARCINOMA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL EDEMA; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; SENSORY NEUROPATHY; SKIN MANIFESTATION; SKIN PAIN; SKIN SWELLING; SKIN ULCER; TREATMENT DURATION; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NIACINAMIDE; OVARIAN NEOPLASMS; PHENYLUREA COMPOUNDS; PLACEBOS; PROTEIN KINASE INHIBITORS;

EID: 84879112772     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.04.011     Document Type: Article

References (27)

1. American Cancer Society Cancer facts and figures, 2012 2012
2. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
3. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology (NCCN guidelines) ovarian cancer version 2.2012 2011
4. J. Hope, and S. Blank Current status of maintenance therapy for advanced ovarian cancer Int J Womens Health 1 2009 173 180
5. T. Foster, T.M. Brown, J. Chang, H.D. Menssen, M.B. Blieden, and T.J. Herzog A review of the current evidence for maintenance therapy in ovarian cancer Gynecol Oncol 115 2009 290 301
6. M. Markman, P.Y. Liu, S. Wilczynski, B. Monk, L.J. Copeland, and R.D. Alvarez Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial J Clin Oncol 21 2003 2460 2465
7. T.J. Herzog, R.L. Coleman, M. Markman, D. Cella, and J.T. Thigpen The role of maintenance therapy and novel taxanes in ovarian cancer Gynecol Oncol 102 2006 218 225
8. L.M. Hess, N. Rong, P.O. Monahan, P. Gupta, C. Thomaskutty, and D. Matei Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis Cancer 116 2010 5251 5260
9. R. Burger Overview of anti-angiogenic agents in development for ovarian cancer Gynecol Oncol 121 2011 230 238
10. L. Dal Lago, V. D'Hondt, and A. Awada Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors Oncologist 13 2008 845 858
11. J.B. Levy, N. Pauloski, D. Braun, M. Derome, J. Jordan, and H. Shi Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006) AACR Meeting Abstracts 2006 2006 213 214
12. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, and H. Rong BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
13. J.M. Lee, G.A. Sarosy, C.M. Annunziata, N. Azad, L. Minasian, and H. Kotz Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity Br J Cancer 102 2010 495 499
14. L.L. Siu, A. Awada, C.H. Takimoto, M. Piccart, B. Schwartz, and T. Giannaris Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer Clin Cancer Res 12 2006 144 151
15. S. Welch, H. Hirte, L. Elit, R. Schilder, L. Wang, and K. MacAlpine Sorafenib in combination with gemcitabine in recurrent epitelial ovarian cancer Int J Gynecol Cancer 20 2010 787 793
16. D. Matei, M.W. Sill, H.A. Lankes, K. DeGeest, R.E. Bristow, and D. Mutch Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial J Clin Oncol 29 2011 69 75
17. P. Gomez, and M.E. Lacouture Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer Oncologist 16 2011 1508 1519
18. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
19. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
20. A. Oza, D. Cibula, A. Oaknin, C. Poole, R. Mathijssen, and G. Sonke Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study J Clin Oncol 30 2012 [Abstract 5001]
21. I. Vergote, F. Joly, D. Katsaros, C. Coens, A. Reinthaller, and M. Hall Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a GCIG and EORTC-GCG study J Clin Oncol 30 2012 [Abstract 5000]
22. F. Kew, K. Galaal, A. Bryant, and R. Naik Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment Cochrane Database Syst Rev 6 2011 1 25
23. L. Bodnar, M. Gornas, and C. Szczylik Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study Gynecol Oncol 123 2011 33 36
24. D. Teoh, and A.A. Secord Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer Int J Gynecol Cancer 22 2012 348 359
25. M. Polcher, M. Eckhardt, C. Coch, M. Wolfgarten, K. Kubler, and G. Hartmann Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer Cancer Chemother Pharmacol 66 2010 203 207
26. R. Ramasubbaiah, S.M. Perkins, J. Schilder, C. Whalen, C.S. Johnson, and M. Callahan Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group Gynecol Oncol 123 2011 499 504
27. N. Matsumura, M. Mandai, T. Okamoto, K. Yamaguchi, S. Yamamura, and T. Oura Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling Cancer Sci 101 2010 2658 2663